A CLINICAL trial that aims to develop a new microbicide which serves as a vaginal ring for preventing women from contracting HIV is on track...
A CLINICAL trial that aims to develop a new microbicide which serves as a vaginal ring for preventing women from contracting HIV is on track, according to its latest review.
Experts says alternative prevention strategies are needed to help African women control HIV given that abstinence and the use of male condoms alone cannot stop the HIV epidemic.
The trial called A Study to Prevent Infection with a Ring for External Use (ASPIRE), which started in 2012 and ends in June 2016, uses a ring made of semi-porous material containing the antiretroviral drug, dapirivine.
The ASPIRE team recruited 630 Zimbabwean women to participate in the study, says Nyaradzo Mgodi, clinical researcher directing the trial, who works for the University of Zimbabwe-University of San Francisco Collaborative Research Programme.
ASPIRE has enrolled 2,629 women in 15 clinical sites in Malawi, South Africa, Uganda and Zimbabwe, according to US National Institutes of Health-funded Microbicide Trials Network, which is leading the study.
The International Partnership for Microbicides (IPM), which developed the technology, says the ring slowly releases the drug, thus offering protection for a month or longer.
Mgodi said the study was reviewed last November by an independent board.
“We are pleased that on its review, the data and safety monitoring board recommended ASPIRE to continue,” she said.
“The ASPIRE team in Zimbabwe remains hopeful in finding the dapirivine ring a safe and effective HIV prevention method for women in Zimbabwe and the whole African continent.
“The vaginal microbicide ring as HIV prevention product will save young women who are eight times more likely to be infected with HIV than young men in southern Africa, for example.”
Brid Delvin, vice-president of product development for IPM, told SciDev.Net: “Our acceptability and clinical research to date has shown that the ring is safe, well-tolerated and acceptable to women, and that they are willing to use it if it proves to be effective against HIV.”
He added: “If the study shows efficacy, IPM — as the product developer and regulatory sponsor — will seek regulatory approval so that women in the countries hardest-hit by the epidemic have affordable access to the ring, ” noting that IPM is already developing multipurpose prevention technologies aimed at tackling and sexually transmitted infections, including HIV.
Auxillia Chideme-Munodawafa, associate professor of health sciences at Africa University in Zimbabwe, commended clinical trials that aim to protect women against getting HIV through heterosexual intercourse.
She however recommended monitoring the adherence and efficacy of products such as the vaginal ring resulting from such studies.
Experts says alternative prevention strategies are needed to help African women control HIV given that abstinence and the use of male condoms alone cannot stop the HIV epidemic.
The trial called A Study to Prevent Infection with a Ring for External Use (ASPIRE), which started in 2012 and ends in June 2016, uses a ring made of semi-porous material containing the antiretroviral drug, dapirivine.
 |
| Trial to assess vaginal ring for curbing HIV ‘on track’ |
ASPIRE has enrolled 2,629 women in 15 clinical sites in Malawi, South Africa, Uganda and Zimbabwe, according to US National Institutes of Health-funded Microbicide Trials Network, which is leading the study.
The International Partnership for Microbicides (IPM), which developed the technology, says the ring slowly releases the drug, thus offering protection for a month or longer.
Mgodi said the study was reviewed last November by an independent board.
“We are pleased that on its review, the data and safety monitoring board recommended ASPIRE to continue,” she said.
“The ASPIRE team in Zimbabwe remains hopeful in finding the dapirivine ring a safe and effective HIV prevention method for women in Zimbabwe and the whole African continent.
“The vaginal microbicide ring as HIV prevention product will save young women who are eight times more likely to be infected with HIV than young men in southern Africa, for example.”
Brid Delvin, vice-president of product development for IPM, told SciDev.Net: “Our acceptability and clinical research to date has shown that the ring is safe, well-tolerated and acceptable to women, and that they are willing to use it if it proves to be effective against HIV.”
He added: “If the study shows efficacy, IPM — as the product developer and regulatory sponsor — will seek regulatory approval so that women in the countries hardest-hit by the epidemic have affordable access to the ring, ” noting that IPM is already developing multipurpose prevention technologies aimed at tackling and sexually transmitted infections, including HIV.
Auxillia Chideme-Munodawafa, associate professor of health sciences at Africa University in Zimbabwe, commended clinical trials that aim to protect women against getting HIV through heterosexual intercourse.
She however recommended monitoring the adherence and efficacy of products such as the vaginal ring resulting from such studies.
- Advertisement -
- Advertisement -
The information is provided by PaHarare Exptreme using online sources and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose.
Any reliance you place on such information is therefore strictly at your own risk.
- Advertisement -
